AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BESLER GIDA VE KİMYA SANAYİ VE TİCARET A.Ş.

Quarterly Report May 8, 2025

10641_rns_2025-05-08_fb1e0b10-0b35-469a-b793-e83556305b5f.pdf

Quarterly Report

Open in Viewer

Opens in native device viewer

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD 1 JANUARY - 31 MARCH 2025 (ORIGINALLY ISSUED IN TURKISH)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED
CONSOLIDATED STATEMENT OF FINANCIAL
POSITION

1-3
CONDENSED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME

4
CONDENSED
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
5
CONDENSED
CONSOLIDATED STATEMENT OF CASH FLOWS

6-7
NOTES TO THE CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
8-39
NOTE 1
GROUP'S ORGANIZATION AND NATURE OF OPERATIONS
8-9
NOTE 2
BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS
9-14
NOTE 3
SEGMENT REPORTING
15
NOTE 4
RELATED PARTY DISCLOSURES
15-18
NOTE 5
TRADE RECEIVABLES AND PAYABLES
19
NOTE 6
OTHER RECEIVABLES AND PAYABLES
20
NOTE 7
INVENTORIES
20
NOTE 8
PREPAID EXPENSES AND DEFERRED REVENUE
21
NOTE 9
INVESTMENT PROPERTIES
21-22
NOTE 10 PROPERTY, PLANT AND EQUIPMENT
23-24
NOTE 11 INTANGIBLE ASSETS
25-26
NOTE 12 GOVERMENT GRANTS AND INCENTIVES
26
NOTE 13 PROVISIONS, CONTINGENT ASSETS AND LIABILITIES
27
NOTE 14 COMMITMENTS AND CONTINGENCIES
28
NOTE 15 OTHER ASSETS AND LIABILITIES
29
NOTE 16 CAPITAL, RESERVES AND OTHER EQUITY ITEMS
29-30
NOTE 17 REVENUE AND COST OF SALES
30
NOTE 18 GENERAL ADMINISTRATIVE EXPENSES, MARKETING EXPENSES, RESEARCH AND
DEVELOPMENT EXPENSES
30-31
NOTE 19 INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES
31
NOTE 20 FINANCIAL INCOME AND EXPENSES
32
NOTE 21 MONETARY GAİN LOSS
32
NOTE 22 INCOME TAXES (INCLUDING DEFERRED TAX ASSETS AND LIABILITIES)
33-34
NOTE 23 EARNING PER SHARE
34
NOTE 24 BORROWINGS
35
NOTE 25 NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS
36-39
NOTE 26 CASH AND CASH EQUIVALENTS
39
NOTE 27 SUBSEQUENT EVENTS
39
CONTENTS PAGE

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF 31 MARCH 2025 AND 31 DECEMBER 2024

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Unaudited Audited
Current Period Prior Period
31 March 31 December
Notes 2025 2024
ASSETS
Current Assets 17,912,559,403 17,992,536,711
Cash and cash equivalents 26 2,119,899,538 2,321,218,063
Trade receivables 5 4,000,250,358 3,899,010,458
- Trade receivables from related parties 4,5 1,981,273,266 2,097,999,400
- Trade receivables from third parties 5 2,018,977,092 1,801,011,058
Other receivables 6 6,581,541,738 6,931,275,954
- Other receivables from related parties 4,6 6,442,333,799 6,705,776,361
- Other receivables from third parties 6 139,207,939 225,499,593
Inventories 7 4,313,956,454 3,954,396,522
Prepaid expenses 8 464,300,526 423,673,137
Current income tax assets 22 91,186,220 193,675,453
Other current assets 15 341,424,569 269,287,124
Non-Current Assets 12,448,322,684 12,605,994,040
Other receivables 6 2,420,391 2,695,013
- Other receivables from third parties 6 2,420,391 2,695,013
Investment properties 9 2,955,213,911 2,955,213,911
Property, plant and equipment 10 8,714,634,819 8,873,104,295
Right of use assets 44,817,768 51,801,662
Intangible assets 11 334,830,587 325,612,903
Prepaid expenses 8 40,748,619 21,338,033
Deferred tax assets 22 355,656,589 376,228,223
TOTAL ASSETS 30,360,882,087 30,598,530,751

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF 31 MARCH 2025 AND 31 DECEMBER 2024

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Unaudited Audited
Current Period Prior Period
31 March 31 December
Notes 2025 2024
LIABILITIES
Current Liabilities 12,591,111,505 12,989,450,383
Short-term borrowings 24 4,402,278,874 4,322,085,723
- Bank loans 24 4,286,415,835 4,233,074,028
- Lease liabilities 24 115,863,039 89,011,695
Current portion of long-term financial
liabilities 24 101,938,250 121,517,219
Trade payables 5 5,791,912,350 5,514,561,231
- Trade payables to related parties 4,5 66,355,325 66,781,782
- Trade payables to third parties 5 5,725,557,025 5,447,779,449
Other payables 6 768,658,489 1,645,161,403
- Other payables to related parties 4,6 768,656,664 1,645,159,394
- Other payables to third parties 6 1,825 2,009
Payables related to employee benefits 266,190,609 168,094,283
Deferred income 8 211,637,025 131,534,600
Current income tax liabilities 22 748,155,245 751,840,494
Short-term provisions 146,984,215 226,780,633
- Short-term provisions for employee benefits 126,899,664 219,538,242
- Other short-term provisions 13 20,084,551 7,242,391
Other current liabilities 15 153,356,448 107,874,797
Non-Current Liabilities 3,950,928,777 3,888,854,935
Long-term borrowings 24 1,273,788,381 1,105,899,109
- Bank loans 24 1,155,549,855 929,627,255
- Lease liabilities 24 118,238,526 176,271,854
Other payables 6 516,796,870 560,051,915
- Other payables to related parties 4,6 516,796,870 560,051,915
Long-term provisions 388,658,949 383,892,983
- Long-term provisions for employee benefits 388,658,949 383,892,983
Deferred income 8 5,978,030 12,297,898
Deferred tax liabilities 22 1,765,706,547 1,826,562,563
Other long term liabilities - 150,467
Total Liabilities 16,542,040,282 16,878,305,318

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF 31 MARCH 2025 AND 31 DECEMBER 2024

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Unaudited Audited
Current Period Prior Period
31 March 31 December
Notes 2025 2024
EQUITY
Paid in capital 16 662,000,000 662,000,000
Share capital adjustment differences 5,130,110,338 5,130,110,338
Other comprehensive income or expenses are
not reclassified to profit or loss 3,088,264,423 3,066,973,005
- Gains on revaluation of plant, property and
equipment 3,289,511,247 3,268,219,829
- Losses on remeasurement of defined benefit
plans (201,246,824) (201,246,824)
Other comprehensive income or expenses to be 557,318,458 569,167,222
reclassified to profit or loss
- Currency translation differences 557,318,458 569,167,222
Share premium 709,911,293 709,911,293
Restricted reserves 16 635,785,976 635,785,976
Effect of business combinations under common
control (1,503,607,761) (1,503,607,761)
Retained earnings / (losses) 3,728,167,023 2,064,872,400
Net profit / (loss) for the year 112,076,281 1,663,294,623
Equity holders of the parent 13,120,026,031 12,998,507,096
Non-controlling interests 698,815,774 721,718,337
Total Equity 13,818,841,805 13,720,225,433
TOTAL LIABILITIES AND EQUITY 30,360,882,087 30,598,530,751

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIODS ENDED 31 MARCH 2025 AND 2024

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Unaudited Current
Period
Unaudited Prior
Period
1 January - 1 January -
Notes 31 March 2025 31 March 2024
Revenue 17 6,924,493,694 7,911,844,764
Cost of sales (-) 17 (5,098,970,425) (6,581,644,032)
GROSS PROFIT 1,825,523,269 1,330,200,732
General administrative expenses (-) 18 (255,087,470) (211,401,216)
Marketing expenses (-) 18 (800,700,884) (856,608,268)
Research and development expenses (-) 18 (16,775,919) (12,560,749)
Other income from operating activities 29,387,200 66,758,238
Other expenses from operating activities (-) (367,371,800) (542,753,230)
OPERATING PROFIT / (LOSS) 414,974,396 (226,364,493)
Income from investment activities 19 860,627,911 398,360,122
Investing activities expenses (-) 19 (1,058,274) (8,354)
OPERATING PROFIT / (LOSS) BEFORE FINANCIAL INCOME /
(EXPENSE)
1,274,544,033 171,987,275
Financial income 20 - 17,151,008
Financial expenses (-) 20 (910,342,579) (534,086,245)
Net monetary position gains 21 (152,090,421) 643,043,844
PROFIT / (LOSS) BEFORE TAX FROM CONTINUING
OPERATIONS
212,111,033 298,095,882
Tax income / (expense) from continuing operations (136,559,071) 182,167,884
- Current tax expense (-) 22 (154,789,190) (4,988,969)
- Deferred tax income / expense(-) 22 18,230,119 187,156,853
PROFIT / (LOSS) FOR THE YEAR 75,551,962 480,263,766
Profit for the year attributable to:
Non-controlling interests (36,524,319) (38,973,927)
Equity holders of the parent 112,076,281 519,237,693
Earnings per share (TRY) 23 0,1693 0,7843
OTHER COMPREHENSIVE INCOME:
Items to not be reclassified subsequently to profit or loss 22,399,589 (310,042,658)
- Gain on revaluation of property, plant and equipment - (249,115,763)
- Actuarial loss on defined benefit plans - (7,586,695)
- Other comprehensive (loss) / income not to be reclassified to (loss) / profit,
tax effect
22,399,589 (53,340,200)
Items to be reclassified subsequently to profit or loss 664,822 (196,722,046)
- Currency translation differences 664,822 (196,722,046)
Other Comprehensive Income / (Expense) 23,064,411 (506,764,704)
TOTAL COMPREHENSIVE INCOME / (EXPENSE) 98,616,373 (26,500,938)
Total comprehensive income / (expense) for the year
attributable to:
Non-controlling interests
(22,902,563) (37,221,828)
Equity holders of the parent 121,518,936 10,720,888

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY FOR THE PERIODS 31 MARCH 2025 AND 2024 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Accumulated other
comprehensive income or
expenses not to be reclassified
to profit or lose
Accumulated
other
comprehensive
income or
expenses to be
reclassified to
profit or lose
Retained earnings
Share capital
adjustment
Gains
/
(losses)
on
revaluation of
plant,
property, and
Losses on
remeasurement
of defined
Currency
translation
Share Restricted Effect of
business
combinations
under common
Retained Net profit /
(loss) for the
Equity holders Non
controlling
Balances as of 1 January 2024 Paid in capital
662,000,000
differences
5,130,110,338
equipment
2,728,818,554
benefit plans
(172,491,561)
differences
759,774,863
premium
709,911,293
reserves
635,785,976
control
(1,503,607,761)
earnings
1,137,139,216
year
927,733,184
of the parent
11,015,174,099
interests
563,673,154
Total equity
11,578,847,253
Transfers - - - - - - - - 927,733,184 (927,733,184) - - -
Total comprehensive income - - (487,813,512) (1,950,946) (26,618,541) - 7,866,194 - - 519,237,693 10,720,888 (37,221,828) (26,500,940)
Balances as of 31 March
2024
662,000,000 5,130,110,338 2,241,005,042 (174,442,507) 733,156,322 709,911,293 643,652,170 (1,503,607,761) 2,064,872,400 519,237,693 11,025,894,987 526,451,326 11,552,346,313
Balances as of 1 January 2025 662,000,000 5,130,110,338 3,268,219,828 (201,246,824) 569,167,222 709,911,293 635,785,976 (1,503,607,761) 2,064,872,400 1,663,294,623 12,998,507,095 721,718,337 13,720,225,432
Transfers - - - - - - - - 1,663,294,623 (1,663,294,623) - - -
Total comprehensive Income - - 21,291,419 - (11,848,764) - - - - 112,076,281 121,518,936 (22,902,563) 98,616,373
Balances as of 31 March 2025 662,000,000 5,130,110,338 3,289,511,247 (201,246,824) 557,318,458 709,911,293 635,785,976 (1,503,607,761) 3,728,167,023 112,076,281 13,120,026,031 698,815,774 13,818,841,805

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIODS ENDED 31 MARCH 2025 AND 2024

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Unaudited Unaudited
Current Period Prior Period
1 January - 1 January -
Notes 31 March 2025 31 March 2024
Cash inflows / (outflows) from operating activities 38,002,324 1,041,376,291
Profit for the year 75,551,962 480,263,766
Adjustments to reconcile profit / (loss) for the year 273,882,448 (219,048,317)
Adjustments related to depreciation and amortization expenses 11 167,718,039 191,391,409
Adjustments related to provision for/ (reversal) of impairment 21,221,298 21,950,841
loss
- Adjustments related to impairment loss on receivables 5 21,268,841 21,358,655
- Adjustments related to impairment (loss) / gain on 7 (47,543) 592,186
inventories, net
Adjustments related to provisions 128,941,370 331,127,109
- Adjustments related to provisions employee benefit 128,366,242 142,755,814
- Adjustments related to lawsuit provisions 575,128 (141,306)
- Other adjustments related to operations - 188,512,601
Adjustments related to interest and commission expenses / (376,305,884) (87,241,396)
(income)
- Adjustments related to interest and commission expense 20 465,765,776 295,977,721
- Adjustments related to interest income 19 (842,071,660) (383,219,117)
Adjustments related to unrealized currency translation 20 410,361,769 199,435,066
differences
Adjustments related to tax (income) / expense 22 136,559,071 (182,167,884)
Adjustments related to gain on disposal of non-current assets 19 165,391 (916,287)
Adjustments for other items caused by cash flows arising from 22,466,335 (17,151,008)
investment or financing activities
Monetary gains / (losses) (237,244,941) (675,476,167)
Changes in working capital (39,208,026) 911,810,282
Changes in trade receivables 5 (122,508,741) 143,861,978
- Changes in trade receivables from non-related parties 5 (239,234,875) 77,074,158
- Changes in trade receivables from related parties 4 116,726,134 66,787,820
Changes in inventories 7 (359,512,389) 2,034,309,313
Changes in other receivables related to operations (64,165,395) (270,658,387)
Changes in trade payables 5 277,351,119 (1,342,375,767)
- Changes in trade payables from non-related parties 5 277,777,576 (1,338,727,325)
- Changes in trade payables from related parties 4 (426,457) (3,648,442)
Changes in other payables related to operations 229,627,380 346,673,145
Cash generated / (used) from operations 310,226,384 1,173,025,731
Cash outflow from paid in employee benefit provisions (216,238,854) (129,882,337)
Taxes paid (55,985,206) (1,767,103)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIODS ENDED 31 MARCH 2025 AND 2024

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

Unaudited Unaudited
Current Period Prior Period
1 January - 1 January -
Notes 31 March 2025 31 March 2024
Cash inflows / (outflows) from investing activities 838,993,335 217,237,929
Payments for purchase of property, plant and equipment and (32,198,176) (203,847,683)
intangible assets
- Payments for purchase of property, plant and equipment 10 (6,463,703) (147,578,291)
- Payments for purchase of intangible assets 11 (25,734,473) (56,269,392)
Proceeds from sale of property, plant and equipment and 10,11,19 10,563,600 23,729,115
intangible assets
Interest income from investment activities 19 842,071,660 383,219,117
Rental income from investment properties 19 18,556,251 14,137,380
Cash inflows / (outflows) from financing activities (841,324,839) (1,148,050,378)
Cash inflows from loans 1,265,312,641 4,374,817,133
Cash outflows from repayment of borrowings (960,358,401) (3,619,061,128)
Payments of lease liabilities (24,198,090) (42,954,434)
Interest and commission paid 20 (465,765,776) (295,977,721)
Net increase / (decrease) in other payables to related parties 6 (656,315,213) (1,564,874,228)
Net decrease in cash and cash equivalents before the effect
of exchange rate changes 35,670,820 110,563,842
Effects of exchange rate changes on cash and cash equivalents (3,120,571) (111,627,784)
Net change in cash and cash equivalents 32,550,249 (1,063,942)
Cash and cash equivalents at the beginning of the year 26 2,321,218,063 70,551,012
Inflation effect on cash and cash equivalents (233,868,774) (10,351,691)
Cash and cash equivalents at the end of the year 26 2,119,899,538 59,135,379

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 1 - GROUP'S ORGANISATION AND NATURE OF OPERATIONS

Main operations of Kerevitaş Gıda Sanayi ve Ticaret Anonim Şirketi ("Kerevitaş" or "the Company") and its subsidiaries ("Group") are production and trading of frozen and canned vegetables and fruits, frozen pastry products, croquettes, canned tuna fish, oil and margarine. Products in the frozen product category; bakery products, vegetables and fruit products, potatoes and croquettes and meat products. Canned product categories; canned tuna, vegetables, and convenience foods, Kerevitaş was initially established in 1978, to export its sea food and has been one of the pioneer food companies since 1990 with "Superfresh" brand.

The Company distributes frozen and canned products that are produced in Bursa and Afyon facilities throughout Türkiye through its dealers and own direct distribution channels, as well as exports its products. The Company has vegetables, fruits, seafood, tuna canned food, bakery products and pizza facilities in its Bursa factory, and has potato, vegetables and fruit production facilities in its Afyon factory.

Kerevitaş has two production plants of oil and margarine in Pendik/İstanbul and in Adana. The third production plant of Kerevitaş was established by the end of 2017 in Sultanate of Brunei.

Donuk Fırıncılık (DFU) produces in its factory in Dudullu Organized Industrial Zone in the Frozen Bakery Products market and sells and markets it in all Türkiye and foreign markets.

The Company's registered office is in Kısıklı Mah, Ferah Cad, Yıldız Holding No:1/A Üsküdar İstanbul.

The ultimate shareholder of the Group is Yıldız Holding A,Ş.

The Company is registered to the Capital Markets Board ("CMB") and its shares have been quoted on the Borsa İstanbul A.Ş. ("BIST") since 1994.

As of 31 March 2025, and 31 December 2024, the principal shareholders and their respective shareholding rates in the Company are as follows:

31 March 2025 31 December 2024
(%) (%)
Yıldız Holding A.Ş. 60,53 60,53
Murat Ülker 9,98 9,98
Other 29,49 29,49
100 100

As of 31 March 2025, the number of employees employed by the Group is 1,975 (31 December 2024: 2,043).

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 1 - GROUP'S ORGANISATION AND NATURE OF OPERATIONS (Continued)

The subsidiaries included in the scope of consolidation of the Group as of 31 March 2025 and 31 December 2023 and respective effective ownership rates are as follows:

Direct and Indirect Effective Ownership %
31 31
March December Countries
Subsidiaries 2025 2024 of activity Nature of business
Production and Trading of
Kerpe Gıda Sanayi ve Tic, A.Ş. 100 100 Türkiye Agricultural and Animal Products
Besmar Gıda Sanayi ve Ticaret Production and Trading of
A.Ş. 100 100 Türkiye Agricultural and Animal Products
Donuk Fırıncılık Ürünleri Production, Buying and Selling of
Sanayi ve Tic, A.Ş. 100 100
Türkiye
Frozen Bakery Products
Berk Enerji Üretimi A.Ş. 88,17 88,17 Türkiye Generation of Electricity
70 70 Production and Trading of Oil
Marsa Yağ Sanayi ve Tic, A.Ş. Türkiye and Oil Products
Western Foods and Pack, SDN Production and Trading of Oil
BHD (*) 70 70 Brunei and Oil Products

(*) The Group has indirect ownership,

Approval of the financial statements

The consolidated financial statements as of and for the period ended 31 March 2025 have been approved by the Board of Directors on May 8, 2025.

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

2,1 - Basis of Presentation

Principles for Preparation of Financial Statements and Significant Accounting Policies

The accompanying consolidated financial statements are prepared in accordance with Communiqué Serial II, No:14,1, "Principles of Financial Reporting in Capital Markets" ("the Communiqué") published in the Official Gazette numbered 28676 on 13 June 2013. According to Article 5 of the Communiqué, consolidated financial statements are prepared in accordance with the Turkish Accounting Standards ("TAS") issued by Public Oversight Accounting and Auditing Standards Authority ("POA"). TAS contains Turkish Accounting Standards, Turkish Financial Reporting Standards ("TFRS") and its addendum and interpretations, In addition, the financial statements have been prepared in accordance with the "Announcement on TFRS Taxonomy" published by POA and the resolution of CMB about the Illustrations of Financial Statements and Application Guidance published on 4 October 2022.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2,1 Basis of Presentation (Continued)

Principles for Preparation of Consolidated Financial Statements and Significant Accounting Policies (Continued)

The condensed consolidated financial statements and notes of the Group have been presented in accordance with the formats announced by the Capital Markets Board (SPK) on 7 June, 2013, and include the required information.

The Company and Subsidiaries in Türkiye maintain their books of accounts and prepare their statutory financial statements in accordance with the Turkish Commercial Code ("TCC"), tax legislation, the Uniform Chart of Accounts issued by the Ministry of Finance and principles issued by CMB. The foreign subsidiaries maintain their books of account in accordance with the laws and regulations in force in the countries in which they are registered. The consolidated financial statements have been prepared under historical cost conventions except for land, buildings, derivatives, financial assets and financial liabilities which are carried at fair value.

The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024.

Functional and Presentation Currency

The individual financial statements of each Group entity are prepared in the currency of the primary economic environment in which the entity operates (its functional currency). The results and financial position of each entity are expressed in TRY, which is the functional currency of the Company, and the presentation currency for the consolidated financial statements.

Financial Reporting in Hyperinflationary Economies

With the announcement made by the Public Oversight Accounting and Auditing Standards Authority (POA) on 23 November 2023, entities applying TFRSs have started to apply inflation accounting in accordance with TAS 29 Financial Reporting in Hyperinflationary Economies for the annual reporting period beginning on or after 31 December 2023, TAS 29 is applied to the financial statements, including the consolidated financial statements, of entities whose functional currency is the currency of a hyperinflationary economy.

In accordance with the standard, financial statements prepared in the currency of a hyperinflationary economy are stated in terms of the purchasing power of that currency at the balance sheet date. For comparative purposes, comparative information in the prior period financial statements is expressed in terms of the measuring unit current at the end of the reporting period, Therefore, the Group has presented its consolidated financial statements as at, 31 December 2024 in terms of the purchasing power of the currency as at 31 March 2025.

In accordance with the CMB's resolution No: 81/1820 dated 28 December 2023, issuers and capital market institutions subject to financial reporting regulations applying Turkish Accounting/Financial Reporting Standards are required to apply inflation accounting by applying the provisions of TAS 29 beginning with the annual financial statements for the accounting periods ending on 31 December 2023.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2,1 Basis of Presentation (Continued)

Financial Reporting in Hyperinflationary Economies (Continued)

The financial statements dated March 31, 2025, have been presented are adjusted for the inflation effect in accordance with the accounting principles specified in TAS 29.

The table below includes the inflation rates calculated based on the Consumer Price Index published by the Turkish Statistical Institute ("TÜİK") for the relevant periods:

Date Index Adjustment Coefficient Three-year cumulative
inflation rates
31.03.2025 2,954,69 1,00000 %250
31.12.2024 2,684,55 1,10063 %291
31.03.2024 2,139,47 1,38104 %309

The main components of the Group's restatement for financial reporting purposes in hyperinflationary economies are as follows:

  • The consolidated financial statements for the current period presented in TRY are expressed in terms of the purchasing power of TRY at the balance sheet date and the amounts for the previous reporting periods are adjusted and expressed in accordance with the purchasing power of TRY at the end of the reporting period.
  • Monetary assets and liabilities are not adjusted since they are currently expressed in terms of the purchasing power at the balance sheet date, Where the inflation-adjusted carrying amounts of nonmonetary items exceed their recoverable amounts or net realisable.
  • Non-monetary assets, liabilities and equity items that are not expressed in terms of the current purchasing power at the balance sheet date have been adjusted by using the relevant adjustment coefficients.
  • All items in the comprehensive income statement, except for the effect of non-monetary items in the balance sheet on the statement of comprehensive income, have been adjusted by applying the coefficients calculated over the periods in which the income and expense accounts were initially recognised in the financial statements.
  • The effect of inflation on the Group's net monetary asset position in the current period is recognised in the gain/(loss) on net monetary position in the consolidated income statement.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2,1 Basis of Presentation (Continued)

Basis of Consolidation

(a) Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group, They are deconsolidated from the date that control ceases.

Inter-Group transactions, balances, and unrealized gains on transactions between group companies are eliminated, Unrealized losses are also eliminated.

(b) Changes in ownership interests in subsidiaries without change of control

Changes in the Group's ownership interests in subsidiaries that do not result in the loss of control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the noncontrolling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recorded directly in equity as the Group's share.

(c) Loss of subsidiary control

When the Group loses control of a subsidiary, a gain or loss is recognized in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognized in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i,e, reclassified to profit or loss or transferred to another category of equity as specified/permitted by applicable TFRS). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under TFRS 9, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.

2.2 New and Amended Turkish Financial Reporting Standards

The accounting policies adopted in preparation of the consolidated financial statements as of March 31, 2025 are consistent with those of the previous financial year, except for the adoption of new and amended TFRS and TFRS interpretations effective as of January 1, 2024 and thereafter. The effects of these standards and interpretations on the Group's financial position and performance have been disclosed in the related paragraphs.

i) Standards, amendments, and interpretations applicable as of 31 March 2025:

Amendment to IAS 1 - Non-current liabilities with covenants; effective from annual periods beginning on or after 1 January 2024, These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2,2 New and Amended Turkish Financial Reporting Standards (Continued)

Amendment to IFRS 16 - Leases on sale and leaseback; effective from annual periods beginning on or after 1 January 2024. These amendments include requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted.

Amendments to IAS 7 and IFRS 7 on Supplier finance arrangements; effective from annual periods beginning on or after 1 January 2024. These amendments require disclosures to enhance the transparency of supplier finance arrangements and their effects on a company's liabilities, cash flows and exposure to liquidity risk. The disclosure requirements are the IASB's response to investors' concerns that some companies' supplier finance arrangements are not sufficiently visible, hindering investors' analysis.

IFRS S1, 'General requirements for disclosure of sustainability-related financial information; effective from annual periods beginning on or after 1 January 2024. This standard includes the core framework for the disclosure of material information about sustainability-related risks and opportunities across an entity's value chain.

IFRS S2, 'Climate-related disclosures'; effective from annual periods beginning on or after 1 January 2024. This is the first thematic standard issued that sets out requirements for entities to disclose information about climate-related risks and opportunities.

ii) Standards, amendments, and interpretations that are issued but not effective as of 31 March 2025:

Amendments to IAS 21 - Lack of Exchangeability; effective from annual periods beginning on or after 1 January 2025, An entity is impacted by the amendments when it has a transaction or an operation in a foreign currency that is not exchangeable into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that creates enforceable rights and obligations.

Amendment to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments; effective from annual reporting periods beginning on or after 1 January 2026 (early adoption is available). These amendments:

• Clarify the requirements for the timing of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system

• Clarify and add further guidance for assessing whether a financial asset meets the solely payments of principal and interest (SPPI) criterion.

• Add new disclosures for certain instruments with contractual terms that can change cash flows (such as some instruments with features linked to the achievement of environment, social and governance (ESG) targets); and

• Make updates to the disclosures for equity instruments designated at Fair Value through Other Comprehensive Income (FVOCI).

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2,2 New and Amended Turkish Financial Reporting Standards (Continued)

  • Annual improvements to IFRS – Volume 11; Annual improvements are limited to changes that either clarify the wording in an Accounting Standard or correct relatively minor unintended consequences, oversights or conflicts between the requirements in the Accounting Standards, The 2024 amendments are to the following standards:
    • IFRS 1 First-time Adoption of International Financial Reporting Standards;
    • IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;
    • IFRS 9 Financial Instruments;
    • IFRS 10 Consolidated Financial Statements; and
    • IAS 7 Statement of Cash Flows.

IFRS 18 Presentation and Disclosure in Financial Statements; effective from annual periods beginning on or after 1 January 2027. This is the new standard on presentation and disclosure in financial statements, with a focus on updates to the statement of profit or loss, The key new concepts introduced in IFRS 18 relate to:

  • The structure of the statement of profit or loss;
  • Required disclosures in the financial statements for certain profit or loss performance measures that are reported outside an entity's financial statements (that is, management-defined performance measures); and
  • Enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general.

IFRS 19 Subsidiaries without Public Accountability: Disclosures; effective from annual periods beginning on or after 1 January 2027. Earlier application is permitted. This new standard works alongside other IFRS Accounting Standards, An eligible subsidiary applies the requirements in other IFRS Accounting Standards except for the disclosure requirements and instead applies the reduced disclosure requirements in IFRS 19. IFRS 19's reduced disclosure requirements balance the information needs of the users of eligible subsidiaries' financial statements with cost savings for preparers, IFRS 19 is a voluntary standard for eligible subsidiaries, A subsidiary is eligible if:

  • It does not have public accountability; and
  • It has an ultimate or intermediate parent that produces consolidated financial statements available for public use that comply with IFRS Accounting Standards.

The effects of standards, amendments and interpretations on Group's consolidated financial statements and performance of are being evaluated by Group.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 3 - SEGMENT REPORTING

Established in Türkiye, the Group's field of activity is the production and trade of frozen and canned fruits and vegetables, frozen and canned sea products, frozen bakery products, croquet, canned tuna fish, oil and margarine, Operating segments are determined and reported in a manner consistent with the reporting provided to the Board of Directors and their strategic decision-making processes.

The Board of Directors and top management monitor the operations of the Group based on the different business units, which are "frozen and canned food" and "edible oil".

The segment revenues and expenses for the periods 1 January - 31 March 2025 and 1 January - 31 March 2024 are as follows:

1 January
Frozen and Canned Edible Oil 31 March 2025
Revenue 2.556.682.060 4.367.811.634 6.924.493.694
Gross Profit 876.011.367 949.511.902 1.825.523.269
Operating Profit 306.854.333 446.104.663 752.958.996
EBITDA (*) 415.407.993 505.269.042 920.677.035
EBITDA/Revenue 16,2% 11,6% 13,3%
Investment 22.187.729 10.010.447 32.198.176
1 January
Frozen and Canned Edible Oil 31 March 2024
Revenue 2.446.168.034 5.465.676.730 7.911.844.764
Gross Profit 523.886.522 806.314.210 1.330.200.732
Operating Profit 25.726.475 223.904.024 249.630.499
EBITDA (*) 171.224.929 269.796.979 441.021.908
EBITDA/Revenue 7,0% 4,9% 5,6%

(*) EBITDA is not a measurement instrument that is prescribed in TAS and it cannot be comparable other entities calculations.

Investment 134.451.872 69.395.811 203.847.683

NOTE 4 - RELATED PARTY DISCLOSURES

Due to related parties, due from related parties and summary of significant transactions with related parties as of 31 March 2025 and 31 December 2024 are as follows.

The related parties listed below are composed of Yıldız Holding group companies.

31 March 31 December
Trade receivables from related parties 2025 2024
Ülker Bisküvi San. A.Ş. 678,808,381 599,968,468
Şok Marketler Tic. A.Ş. 419,154,836 324,367,975
Yeni Teközel Markalı Ürünler Dağıtım Hizmetleri A.Ş. 314,052,622 351,694,932
G2mEksper Satış ve Dağıtım Hizmetleri A.Ş. 238,811,994 429,301,081
Horizon Hızlı Tüketim Ürünleri Paz. ve Tic. A.Ş. 195,083,281 153,600,771
Bizim Toptan Satış Mağazaları A.Ş. 63,404,134 179,429,416
E Star Global E Ticaret Satış ve Pazarlama A.Ş. 34,831,709 35,351,021
Other 37.126.309 24.285.736
Total 1,981,273,266 2,097,999,400

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

31 March 31 December
Trade payables to related parties 2025 2024
İzsal Bilgi Sistemleri ve Gayrimenkul Geliştirme A.Ş. 23,219,916 34,188,683
G2mEksper Satış ve Dağıtım Hizmetleri A.Ş. 17,978,482 10,894,623
Aytaç Gıda Yatırım San. Tic. A.Ş. 10,676,657 3,529,484
Ülker Bisküvi San. A.Ş. 2,469,935 4,103,422
Sağlam İnşaat Taahhüt Tic. A.Ş. 1,883,794 3,120,981
Bizim Toptan Satış Mağazaları A.Ş. 1,622,742 -
Northstar Araştırma Geliştirme Marka Yönetimi ve 1,430,767 1,574,742
Danışmanlık A.Ş.
Adapazarı Şeker Fabrikası A.Ş. 1,369,343 1,935,281
Penta Teknoloji Ürünleri Dağıtım Tic. A.Ş. 328,155 2,614,116
Other 5,375,534 4,820,450
Total 66,355,325 66,781,782

NOTE 4 - RELATED PARTY DISCLOSURES (Continued)

Due from related parties and due to related parties' balances comprised of purchasing and selling goods and services. Supply of goods comprise of mainly purchases of raw materials.

31 March 31 December
Other receivables from related parties 2025 2024
Yıldız Holding A.Ş.(*) 6,442,333,799 6,705,776,361
6,442,333,799 6,705,776,361
31 March 31 December
Other payables to related parties 2025 2024
Yıldız Holding A.Ş.(*) 768,656,664 1,645,159,394
768,656,664 1,645,159,394
31 March 31 December
Other non-current payables to related parties 2025 2024
Yıldız Holding A.Ş.(**) 516,796,870 560,051,915
516,796,870 560,051,915

(*) The relevant amount consists of balances made available from Yıldız Holding and to Yıldız Holding for financing purposes, and these balances do not have a certain maturity. Interest rates are re-determined on a monthly basis, taking into account market conditions, and as of 31 March 2025, the average interest rates of TRY-based receivables and payables are 43,54% (31 December 2024: 48,71%).

(**) As of 12 April 2018, Yıldız Holding A,Ş and some Yıldız Holding Group entities including Group, signed a syndicated loan agreement with creditors. Thus, the Group's borrowings to banks were transferred to Yıldız Holding, Total of the long-term payables of the Group to Yıldız Holding is composed of syndicated debts.

The amount of collateral given as guarantor ship and mortgage within the scope of the syndication debts is TRY11,175,958,336 (31 December 2024: TRY11,976,610,677).

Transactions with related parties comprised of purchasing and selling goods and services. Purchases are mainly comprised of purchases of raw materials.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 4 - RELATED PARTY DISCLOSURES (Continued)

1 January - 1 January -
Sale of goods and services 31 March 2025 31 March 2024
Ülker Bisküvi San. A.Ş. 1.162.921.446 1.430.960.530
Şok Marketler Ticaret A.Ş. 470,911,876 278,114,253
Yeni Teközel Markalı Ürünler Dağıtım Hizmetleri A.Ş. 451,951,304 589,685,318
G2mEksper Satış ve Dağıtım Hizmetleri A.Ş. 327,844,685 431,948,275
Horizon Hızlı Tüketim Ürünleri Paz. Sat. ve Dağ. A.Ş. 285,768,204 333,652,175
Bizim Toptan Satış Mağazaları A.Ş. 89,999,718 124,412,705
E Star Global E-Ticaret Satış ve Pazarlama A.Ş. 29,564,094 71,030,070
CCC Dış Ticaret A.Ş. 10,409,269 4,221,280
Other 2,823 4,108,515
Total 2,829,373,419 3,268,133,121
1 January - 1 January -
Purchase of goods and services 31 March 2025 31 March 2024
Maia International B.V. 766,744,272 798,175,415
Yıldız Holding A.Ş. 115,337,141 94,339,758
İzsal Bilgi Sistemleri ve Gayrimenkul Geliştirme A.Ş. 53,825,250 38,103,759
Aytaç Gıda Yatırım San. Tic. A.Ş. 17,199,997 38,378,487
Sağlam İnşaat Taahhüt Tic. A.Ş. 11,919,872 10,626,507
Ülker Bisküvi San. A.Ş. 10,101,955 2,454,869
G2mEksper Satış ve Dağıtım Hizmetleri A.Ş. 6,193,237 6,605,074
Horizon Hızlı Tüketim Ürünleri Paz. Sat. ve Dağ. A.Ş. 2,532,822 3,054,404
UCZ Mağazacılık Ticaret A.Ş. 1,602,612 -
Other 4,366,959 6,619,409
Total 989,824,117 998,357,682
1 January - 1 January -
31 March 31 March
Service, rent and other income 2025 2025
Yıldız Holding A.Ş. 3,510,204 2,249,372
İzsal Bilgi Sistemleri ve Gayrimenkul Geliştirme A.Ş. 455,470 -
Sağlam İnşaat Taahhüt Tic. A.Ş. 331,844 326,780
Bizim Toptan Satış Mağazaları A.Ş. 314,877 312,474
Other 450,796 281,865
Total 5,063,191 3,170,491

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 4 - RELATED PARTY DISCLOSURES (Continued)

1 January - 1 January -
Commission and financial expense 31 March 2025 31 March 2024
Yıldız Holding A.Ş. 128,440,912 84,507,059
Pervin Finansal Kiralama A.Ş. 6,629,526 7,090,057
Other 116,155 -
Total 135,186,593 91,597,116
1 January - 1 January -
Commission and financial income 31 March 2025 31 March 2024
Ülker Bisküvi San. A.Ş. 45,165,628 -
Other 2,305,794 -
Total 47,471,422 -
Investment income 1 January -
31 March 2025
1 January -
31 March 2024
Yıldız Holding A.Ş. (*) 835,578,690 383,434,497
Total 835,578,690 383,434,497

(*) Income from investment activities obtained from Yıldız Holding comprised of interest and exchange differences.

Key management compensation:

Key management personnel of the Company consist of the members of Board of Directors and members of Executive Board. The compensation of key management personnel comprises salaries, bonus, health insurance and transportation, The compensation of key management during the years are as follows:

1 January -
31 March 2025
1 January -
31 March 2024
Salaries and other benefits 70,552,494 60,251,326
70,552,494 60,251,326

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 5- TRADE RECEIVABLES AND PAYABLES

As of 31 March 2025 and 31 December 2024 trade receivables of the Group are as follows:

Current trade receivables 31 March
2025
31 December
2024
Trade receivables (*) 2,076,371,894 1,838,615,547
Notes receivable 17,256,163 21,327,343
Income accruals 13,520 1,336,624
Provision for doubtful receivables (-) (74,664,485) (60,268,456)
Trade receivables, net 2,018,977,092 1,801,011,058
Trade receivables from related parties (Note 4) (**) 1,981,273,266 2,097,999,400
4,000,250,358 3,899,010,458

(*) Progress accruals arising from sales to customers are netted off with trade receivables.

(**) Trade receivables from related parties mainly comprised from sales of goods. Purchases are mainly comprised of purchases of raw materials.

Average maturity for trade receivables is 51 days (31 December 2024: 53).

Movements of provision for doubtful receivables as of 1 January - 31 March 2025 and 1 January - 31 March 2024 are as follows:

1 January - 1 January -
Movement of provision for doubtful receivables 31 March 2025 31 March 2024
Opening balance (60,268,456) (74,323,562)
Charge for the year (-) (21,416,996) (22,978,145)
Reversals of provisions 148,155 1,619,490
Monetary gain / (loss) 6,872,812 8,887,602
End of the period (74,664,485) (86,794,615)
31 March 31 December
Short-term trade payables 2025 2024
Trade payables 5,548,245,967 5,293,244,165
Expense accruals 177,311,058 154,535,284
Trade payables, net 5,725,557,025 5,447,779,449
Trade payables to related parties (Note 4) (*) 66,355,325 66,781,782
5,791,912,350 5,514,561,231

(*) Trade payables to related parties mainly comprised from purchases of goods and services. Purchases are mainly comprised of purchases of raw materials.

Average maturity for trade payables is 100 days (31 December 2024: 101).

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 6 - OTHER RECEIVABLES AND PAYABLES

Other Receivables

31 March 31 December
Other current receivables 2025 2024
Receivables from related parties (Note 4) 6,442,333,799 6,705,776,361
Receivables from tax administration 133,588,941 217,547,841
Other miscellaneous receivables 5,618,998 7,951,752
6,581,541,738 6,931,275,954
31 March 31 December
Other non-current receivables 2025 2024
Deposits and guarantees given 2,420,391 2,695,013
2,420,391 2,695,013

Other Payables

Other current liabilities 31 March
2025
31 December
2024
Payables to related parties (Note 4) 768,656,664 1,645,159,394
Other miscellaneous liabilities 1,825 2,009
768,658,489 1,645,161,403
Other non-current liabilities 31 March
2025
31 December
2024
Non-current liabilities to related parties (Note 4) 516,796,870 560,051,915
516,796,870 560,051,915

NOTE 7 - INVENTORIES

31 March 31 December
2025 2024
Raw materials 1,924,384,378 1,829,974,834
Work in process 1,248,854,434 1,192,340,615
Finished goods 803,737,961 686,058,983
Trade goods 173,050,008 98,823,621
Other inventory (*) 164,402,135 147,718,474
Provision for impairment of inventory (-) (472,462) (520,005)
4,313,956,454 3,954,396,522

(*) Other inventories consist of packaging and technical operating materials.

Movements of provision for impairment of inventories as of 1 January - 31 March 2025 and 1 January - 31 March 2024 are as follows:

1 January - 1 January -
31 March 2025 31 March 2024
Opening balance (520,005) (2,553,540)
Charge for the year - (720,800)
Reversals of provisions 47,543 128,614
Reversals of provisions during the period - 894,558
Closing balance (472,462) (2,251,168)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 8 - PREPAID EXPENSES AND DEFERRED REVENUE

31 March 31 December
Short-term prepaid expenses 2025 2024
Advances given for inventory purchases 390,968,464 303,912,579
Prepaid expenses 72,595,667 119,541,282
Business advances 736,395 219,276
464,300,526 423,673,137
Long-term prepaid expenses 31 March
2025
31 December
2024
Advances given for fixed asset purchases 40,748,619 21,338,033
40,748,619 21,338,033
31 March 31 December
Short-term deferred income 2025 2024
Advances received 205,949,247 128,043,119
Deferred income 5,687,778 3,491,481
211,637,025 131,534,600
Long-term deferred income 31 March
2025
31 December
2024
Deferred income 5,978,030 12,297,898
5,978,030 12,297,898

NOTE 9 - INVESTMENT PROPERTIES

Cost value 1 January 2025 Disposals Transfers Change in fair value 31 March 2025
Land, building, plant
machinery and devices
2,955,213,911 - - - 2,955,213,911
2,955,213,911 - - - 2,955,213,911
Cost value 1 January 2024 Disposals Transfers Change in fair value 31 March 2024
Land, building, plant
machinery and devices
2,109,897,063 - - - 2,109,897,063
2,109,897,063 - - - 2,109,897,063

The Group has earned rent income from its investment properties amounting to TRY18,556,251 in the current period. (1 January - 31 March 2024: TRY14,137,380) (Note 19).

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 9 - INVESTMENT PROPERTIES (Continued)

Fair value of investment properties

31 March 2025
Level 1 Level 2 Level 3
Investment properties - 2,955,213,911 -
Total - 2,955,213,911 -
31 March 2024
Level 1 Level 2 Level 3
Investment properties - 2,109,897,063 -
Total - 2,109,897,063 -

As of 31 March 2025, the Group's investment properties are carried with their fair values determined by the revaluation carried out on 31 December 2024, and these fair values have been determined by an independent valuation firm holding a CMB License. The change between the fair value and cost value of the investment properties at initial recognition is included under equity. Gains or losses arising from changes in fair value in subsequent measurement periods are included in the consolidated statement of profit or loss.

The table above present the fair value hierarchy of investment properties of the Group as of 31 March 2025 and 31 December 2024. The levels of hierarchies of fair values are detailed below.

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Inputs for the asset or liability that are not based on observable market data

Valuation techniques used to derive level 2 fair values,

Level 2 fair values of investment properties have been derived using the sales comparison approach. Sales prices of comparable land and buildings in proximity are adjusted for differences in key attributes such as property size. The most significant input into this valuation approach is price per square foot.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 10 - PROPERTY, PLANT AND EQUIPMENT

1 January Currency 31 March
Cost value 2025 Additions Disposals Transfers Revaluation translation differences 2025
Land and land improvements 3,835,647,927 - - - - (3,359) 3,835,644,568
Buildings 4,451,297,342 - (30,839,496) - - (8,380,095) 4,412,077,751
Machinery and equipment 6,451,427,221 2,170,372 - - - (2,016,625) 6,451,580,968
Motor vehicles 23,016,029 - - - - (22,884) 22,993,145
Furniture and fixtures 588,783,169 1,341,430 (48,194) - - (184,958) 589,891,447
Leasehold improvements 66,444,093 - - - - - 66,444,093
Other tangibles (*) 400,803,240 - (1,471,734) - - - 399,331,506
Construction in progress 4,794,728 2,951,901 - - - - 7,746,629
15,822,213,749 6,463,703 (32,359,424) - - (10,607,921) 15,785,710,107
1 January Currency 31 March
Accumulated depreciation 2025 Additions Disposals Transfers Revaluation translation differences 2025
Land improvements (16,190,790) (2,028,431) - - - 1,511 (18,217,710)
Buildings (1,689,287,354) (40,514,361) 20,210,321 - - 1,157,867 (1,708,433,527)
Machinery and equipment (4,486,544,089) (86,934,687) - - - 952,086 (4,572,526,690)
Motor vehicles (20,270,320) (270,500) - - - 21,537 (20,519,283)
Furniture and fixtures (439,537,267) (9,301,609) 44,319 - - 92,057 (448,702,500)
Leasehold improvements (52,386,021) (1,101,369) - - - - (53,487,390)
Other tangibles (*) (244,893,613) (5,670,368) 1,375,793 - - - (249,188,188)
(6,949,109,454) (145,821,325) 21,630,433 - - 2,225,058 (7,071,075,288)
Net book value
8,873,104,295
8,714,634,819
--------------------------------- ---------------

(*) Other tangibles comprised of refrigerators.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

1 January Currency 31 March Cost value 2024 Additions Disposals Transfers Revaluation translation differences 2024 Land and land improvements 2,905,793,324 - - - - (260,954) 2,905,532,370 Buildings 4,905,804,584 9,389,312 - - - (93,119,203) 4,822,074,693 Machinery and equipment 6,296,060,557 19,427,845 (31,254,069) - - (22,769,698) 6,261,464,635 Motor vehicles 23,826,791 - - - - (495,236) 23,331,555 Furniture and fixtures 598,928,248 1,282,329 (437,629) - - (1,213,499) 598,559,449 Leasehold improvements 63,693,373 38,553,858 - - - - 102,247,231 Other tangibles (*) 412,222,908 47 (4,742,919) - - - 407,480,036 Construction in progress 2,115,650 78,924,901 - - - - 81,040,551 15,208,445,435 147,578,292 (36,434,617) - - (117,858,590) 15,201,730,520

NOTE 10 - PROPERTY, PLANT AND EQUIPMENT (Continued)

Accumulated 1 January Currency 31 March
depreciation 2024 Additions Disposals Transfers Revaluation translation differences 2024
Land improvements (37,928,145) (5,248,056) - - - 975,901 (42,200,300)
Buildings (1,597,016,482) (84,789,742) - - - 18,870,792 (1,662,935,432)
Machinery and equipment (4,255,653,725) (72,578,896) 31,073,844 - - 7,655,573 (4,289,503,204)
Motor vehicles (21,173,841) (681,745) - - - 563,795 (21,291,791)
Furniture and fixtures (412,979,124) (11,749,262) 138,634 - - (2,577,017) (427,166,769)
Leasehold improvements (47,716,287) (1,469,375) - - - - (49,185,662)
Other tangibles (*) (244,541,135) (6,581,955) 3,751,408 - - - (247,371,682)
(6,617,008,739) (183,099,031) 34,963,886 - - 25,489,044 (6,739,654,840)

Net Book Value 8,591,436,696 8,462,075,680

(*) Other tangible assets consist of refrigerated cabinets.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 11 - INTANGIBLE ASSETS

Currency
1 January translation 31 March
Cost value 2025 Additions Disposals Transfers differences 2025
Rights 238,635,129 4,707,268 - - - 243,342,397
Development expenses 532,609,919 21,027,204 - - - 553,637,123
Other intangible assets 7,513,037 - - - - 7,513,037
778,758,085 25,734,472 - - - 804,492,557
Accumulated
amortization
1 January
2025
Additions Disposals Transfers Currency
translation
differences
31 March
2025
Rights (177,211,477) (3,072,323) - - - (180,283,800)
Development expenses (268,420,835) (13,444,465) - - - (281,865,300)
Other intangible assets (7,512,870) - - - - (7,512,870)
(453,145,182) (16,516,788) - - - (469,661,970)
Net Book Value 325,612,903 334,830,587
Cost Value 1 January
2024
Additions Disposals Transfers Currency
translation
differences
31 March
2024
Rights 304,824,814 28,251,657 (21,342,096) - (1,605,079) 310,129,296
Development
expenses
450,460,671 28,017,734 - - - 478,478,405
Other intangible
assets
7,513,038 - - - - 7,513,038

762,798,523 56,269,391 (21,342,096) - (1,605,079) 796,120,739

Accumulated
amortization
1 January
2024
Additions Disposals Transfers Currency
translation
differences
31 March
2024
Rights (170,556,452) (2,373,488) - - 5,242,522 (167,687,418)
Development (215,067,599) (928,770) - - - (215,996,369)
expenses
Other intangible
assets
(7,512,870) - - - - (7,512,870)
(393,136,921) (3,302,258) - - 5,242,522 (391,196,657)
Net Book Value 369,661,602 404,924,082

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025

(Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 11 - INTANGIBLE ASSETS (Continued)

Allocation of depreciation and amortization expenses of property, plant and equipments, intangible assets, and right-of-use assets as of 1 January - 31 March 2025 and 1 January - 31 March 2024 are as follows:

1 January -
31 March
1 January -
31 March
2025 2024
Cost of sales (130,158,880) (173,400,961)
Marketing, sales and distribution expense (Note 18) (19,766,524) (12,350,323)
General administration expenses (Note 18) (8,541,052) (3,494,976)
Research and development expenses (Note 18) (9,251,583) (2,145,149)
(167,718,039) (191,391,409)

NOTE 12 - GOVERNMENT GRANTS AND INCENTIVES

Investment Incentive Certificate numbered 535745 was received from the General Directorate of Incentives, Implementation and Foreign Capital of the Ministry of Industry and Technology of the Republic of Türkiye on April 21, 2022. The validity period of the Incentive Certificate is 3 years and expires on April 13, 2025, The support elements foreseen in the Investment Incentive Certificate are 100% customs exemption and Value Added Tax exemption, 2-year insurance premium employer share support and 50% Tax Deduction. The total amount of investment foreseen in the Investment Incentive Certificate is TRY99,936,725. As of March 31, 2025, the investment amount realized within the scope of the incentive certificate is TRY18,608,237.

Investment Incentive Certificate numbered 552413 was received from the General Directorate of Incentives, Implementation and Foreign Capital of the Ministry of Industry and Technology of the Republic of Türkiye on April 26, 2023. The validity period of the said Incentive Certificate is 3 years and expires on April 25, 2026. The validity period of the mentioned Incentive Certificate is 3 years and ends on 25 April 2026. The support elements foreseen in the Investment Incentive Certificate are 100% customs exemption and Value Added Tax exemption, 7 years of insurance premium employer's share support, 80% Tax Reduction and 40% Investment Contribution Rate support. Total amount of the investment foreseen in the Investment Incentive Certificate is TRY86,414,080. As of 31 March 2025, the amount of investment realized within the scope of the incentive certificate is TRY51,212,62.

The Group's rights that can be used by all companies that meet the criteria required by the legislation, regardless of sector; Incentives within the scope of research and development law (100% corporate tax, VAT exemption, etc,), inward processing permits, social security institution incentives and employer's insurance premium support.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 13 - PROVISIONS, CONTINGENT ASSETS AND LIABILITIES

Contingent Assets and Liabilities

Contingent assets and liabilities as of 31 March 2025, and 31 December 2024 are as follows:

31 March 31 December
Contingent assets 2025 2024
Letters of guarantees received 1,515,359,419 1,501,729,869
Bonds of guarantee received 35,016,532 7,842,357
Pledges and mortgages received 198,670 218,662
1,550,574,621 1,509,790,888

Letter of guarantees received, and mortgages received are comprised of the guarantees received from customers within the scope of credit risk.

31 March 31 December
Contingent liabilities 2025 2024
Mortgages given (*) 9,527,442,398 9,757,243,185
Guarantorship given (*) 5,408,979,336 5,629,314,042
Letters of guarantee given 1,426,360,379 1,328,003,858
16,362,782,113 16,714,561,085

(*) Mortgages and guarantees given are given as Yıldız Holding syndication loan guarantees.

31 March 31 December
Other short-term provisions 2025 2024
Provisions for cost expenses 15,898,209 3,267,789
Provisions for lawsuits 4,186,342 3,974,602
20,084,551 7,242,391

The movements of provisions for lawsuits as of 1 January - 31 March 2025 and 1 January - 31 March 2024 are as follows:

1 January - 1 January -
Movement of provision for lawsuits 31 March 2025 31 March 2024
Opening 3,974,602 5,268,564
Charge / (reversals) for the period 575,128 (141,306)
Monetary gain / (loss) (363,388) (689,737)
End of the period 4,186,342 4,437,521

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 14 - COMMITMENTS AND CONTINGENCIES

Guarantee, pledge and mortgages given by the Group

Guarantee, pledge and mortgages ("GPM") in respect of commitment and contingencies realized in the ordinary course of business given for the periods ended 31 March 2025 and 31 December 2024 are as follows:

31 March 2025 31 December 2024
Original Currency Amount TRY Equivalent Original Currency Amount TRY equivalent
A.
CPMs given for Company's own legal personality
TRY 11,390,886,738 11,390,886,738 TL 13,344,566,214 13,344,566,214
(*) EUR 122,153,889 4,971,895,375 EUR 83,347,885 3,369,994,871
B.
CPMs given on behalf of fully consolidated
companies - - - -
C.
CPMs given in the normal course of business
activities on behalf of third parties - - - -
D.
Total amount of other CPMs
- - - -
i) Total amount of CPMs given on behalf of the parent - - - -
ii) Total amount of CPMs given to on behalf of other
Group
companies which are not in scope of B and C - - - -
iii) Total amount of CPMs given on behalf of third
parties which are not in scope of C - - - -
16,362,782,113 16,714,561,085

As of 31 March 2025, the Group has export commitments of EUR 15,000,000 (31 December 2024: TRY39,335,975) The fulfillment period of export commitments is two years.

(*) On February 2018, Yıldız Holding A.Ş. started negotiations with the creditors in order to refinance the loan payables for which no guarantee was provided and the balances which are used by the itself and by various Yıldız Holding group entities in connection with the miscellaneous loan agreements the Holding company entered into with Turkish banks. The purpose of these negotiations is to move all loan payable balances to the level of Yıldız Holding A.Ş. within the framework of a single maturity, interest rate and payment plan.

The bank loans of the Company and its subsidiaries which in total TRY6,607 million in cash (Nominal: TRY745 Million) and TRY1,791 million non-cash (Nominal: TRY202 million) contingencies were moved to the level of Yıldız Holding A.Ş. through syndication. The Company's total debt has not increased as a result of the syndicated loan, but cash and non-cash loans are moved to Yıldız Holding A.Ş. level.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 15 - OTHER ASSETS AND LIABILITIES

31 March 31 December
Other current assets 2025 2024
Deferred VAT 332,034,520 255,475,922
Other 9,390,049 13,811,202
341,424,569 269,287,124
31 March 31 December
Other current liabilities 2025 2024
Taxes and funds payables 103,880,593 51,742,680
Other current liabilities 49,475,855 56,132,117
153,356,448 107,874,797

NOTE 16 - CAPITAL, RESERVES AND OTHER EQUITY ITEMS

As of 31 March 2025, the Company's capital was issued and consisted of 66,200,000,000 shares, each with a nominal value of TRY0,01, (31 December 2024: 66,200,000,000 shares).

The Group's shareholders and their share in the capital as of 31 March 2025 and 31 December 2024 are as follows:

31 March 2025 31 December 2024
Shareholders Share (%) Amount Share (%) Amount
Yıldız Holding A.Ş. 60,53 400,675,745 60,53 400,675,745
Murat Ülker 9,98 66,079,898 9,98 66,079,898
Other 29,49 195,244,357 29,49 195,244,357
Total 100 662,000,000 100 662,000,000

Restricted Reserves and Retained Earnings

The legal reserves consist of first and second legal reserves, appropriated in accordance with the Turkish Commercial Code, The first legal reserves are appropriated out of historical statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the historical paid-in share capital. The second legal reserves are appropriated after the first legal reserves and dividends, at the rate of 10% per annum of all cash dividend distributions, These reserves can only be used to cover losses, to maintain the company in times when things are not going well, or to prevent unemployment and to mitigate the effects of such losses, unless they exceed half of the paid-in capital of the company.

Restricted reserves allocated from profit as of March 31, 2025, are as follows. There is no remaining profit for the period after deducting previous years' losses in the legal records of the Group and there are no other resources that can be subject to profit distribution.

31 March 31 December
Restricted reserves 2025 2024
Legal reserves 635,785,976 635,785,976
635,785,976 635,785,976

These are reserves set aside from the profits of previous periods due to obligations arising from the law or contract or for certain purposes other than profit distribution. These reserves are shown based on their amounts in legal records, and the differences arising from the evaluations made within the framework of TFRS are associated with previous years' profits and losses.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 16 - CAPITAL, RESERVES AND OTHER EQUITY ITEMS (Continued)

31 March 2025 (In accordance with Inflation
TFRS) Nominal value adjustment effect Indexed Value
Paid capital 662,000,000 5,130,110,338 5,792,110,338
Legal reserves 37,378,879 598,407,097 635,785,976
31 March 2025 (In accordance with Inflation
Tax Law) Nominal value adjustment effect Indexed Value
Paid capital 662,000,000 6,701,186,125 7,363,186,125

Legal reserves 44,837,076 908,859,513 953,696,589

NOTE 17 - REVENUE AND COST OF SALES

1 January - 1 January -
31 March 2025 31 March 2024
Domestic sales 8,372,577,049 8,994,639,764
Export sales 677,616,641 795,937,370
Other income 23,882,829 38,310,863
Gross sales 9,074,076,519 9,828,887,997
Sales returns and discounts (-) (2,149,582,825) (1,917,043,233)
Net sales 6,924,493,694 7,911,844,764
Cost of sales (-) (5,098,970,425) (6,581,644,032)
Gross profit 1,825,523,269 1,330,200,732

NOTE 18 - GENERAL ADMINISTRATIVE EXPENSES, MARKETING EXPENSES, RESEARCH AND DEVELOPMENT EXPENSES

Marketing, sales and
distribution expenses
1 January -
31 March 2025
1 January -
31 March 2024
Personnel expenses (199,732,049) (166,625,683)
Advertisement expenses (197,950,664) (204,480,658)
Transportation expenses (180,302,163) (214,043,246)
Tax duties and fees (*) (78,304,609) (77,660,609)
Brand usage expense (39,435,553) (54,703,093)
Rent expenses (28,881,450) (28,602,803)
Depreciation and amortization expense (Note 11) (19,766,524) (12,350,323)
Export expenses (11,677,187) (10,369,693)
Externally provided benefits and services (11,635,681) (2,702,739)
Energy expenses (10,699,937) (12,166,739)
Maintenance and repair expenses (6,520,678) (4,912,856)
Other (15,794,389) (67,989,826)
(800,700,884) (856,608,268)

(*) These are expenses incurred regarding the recycling contribution fee (RCF).

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 18 - GENERAL ADMINISTRATIVE EXPENSES, MARKETING EXPENSES, RESEARCH AND DEVELOPMENT EXPENSES (Continued)

1 January - 1 January -
General administrative expenses 31 March 2025 31 March 2024
Externally provided benefits and services (138,518,343) (101,773,258)
Personnel expenses (89,102,562) (85,950,714)
Depreciation and amortization expense (Note 11) (8,541,052) (3,494,976)
Energy expenses (1,735,165) (1,781,513)
Rent expenses (1,613,065) (3,620,089)
Brand copyright expenses (1,041,048) (1,487,779)
Communication expenses (1,003,363) (818,148)
Travel expenses (683,206) (564,049)
Fees, duties and charges (649,948) (445,107)
Building expenses (566,595) (2,223,369)
Other (11,633,123) (9,242,214)
(255,087,470) (211,401,216)
1 January - 1 January -
Research and development expenses 31 March 2025 31 March 2024
Depreciation and amortization expense (Note 11) (9,251,583) (2,145,149)
Personnel expenses (6,611,768) (4,556,105)
Externally provided benefits and services (236,730) (305,122)
Analysis expenses (140,083) -
Other (535,755) (5,554,373)
(16,775,919) (12,560,749)

NOTE 19 - INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES

1 January - 1 January -
Income from Investment Activities 31 March 2025 31 March 2024
Interest income 842,071,660 383,219,117
Rent income 18,556,251 14,137,380
Gain on sale of fixed assets - 916,287
Exchange difference income - 87,338
860,627,911 398,360,122
1 January - 1 January -
Expenses from Investment Activities 31 March 2025 31 March 2024
Exchange difference expenses (892,883) -
Loss on sale of fixed assets (165,391) -
Other - (8,354)
(1,058,274) (8,354)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 20 - FINANCIAL INCOME AND EXPENSES

1 January - 1 January -
Financial income 31 March 2025 31 March 2024
Discount income from financing (*) - 17,151,008
- 17,151,008
1 January - 1 January -
Financial expense 31 March 2025 31 March 2024
Interest expense (424,444,926) (216,858,723)
Exchange difference expenses on loans (410,361,769) (199,435,066)
Commission expenses (41,320,850) (79,118,998)
Financing obligation regarding severance pay (21,573,452) -
Discount expenses from financing (*) (12,641,582) (38,673,458)
(910,342,579) (534,086,245)

(*) The positive/negative difference between the interest rate which is understood within the framework of the renovation agreement within the framework of the unionized loan in other long -term commercial debts of Group to Yıldız Holding A.Ş. and the interest rates valid in the market were accountable in accordance with TFRS 9.

NOTE 21 – MONETARY GAİN LOSS

Non-monetary items 31 March 2025
Financial statement items (416.645.279)
Inventories 84.020.682
Prepaid expenses (short term) (22.099.684)
Property, plant and equipment 873.258.969
Intangible assets 14.932.372
Deferred tax liability (153.398.467)
Paid-in capital (529.558.325)
Other accumulated comprehensive income or expense (280.384.606)
not to be reclassified to profit or loss
Capital reserves (2.033.227)
Premiums related to shares (168.450.528)
Restricted reserves allocated from profits (63.710.421)
Effect of combinations involving entities or entities under common control (137.471.139)
Retained earnings / (losses) (31.750.905)
Profit or loss statement items 264.554.858
Revenue (168.150.390)
Cost of sales 360.899.052
Research and development expenses 5.949.394
Marketing, selling and distribution expenses 27.398.722
General administrative expenses 10.550.666
Income/expenses from investing activities (20.808.344)
Other income/expenses from operating activities 9.798.291
Financing income/expenses 19.056.443
Current tax expense 19.861.024
Net monetary position gains / (losses) (152.090.421)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 22 - INCOME TAXES (INCLUDING DEFERRED TAX ASSETS AND LIABILITIES)

The Group is subject to Turkish corporate taxes. Provision is made in the accompanying financial statements for the estimated charge based on the Group's results for the years and periods. Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, current income taxes recognized in the accompanying consolidated financial statements, have been calculated on a separate-entity basis.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding back non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized,

In Türkiye, the corporate tax rate is 25% as of 31 March 2025 (31 December 2024: 25%). The corporate tax rate is applied to the net corporate income to be found as a result of adding the expenses that are not accepted as deductible in accordance with the tax laws to the commercial income of the corporations and deducting the exceptions and deductions in the tax laws,

The Corporate tax rate is applied to the corporate income of the corporations, which is the result of the addition of expenses that are not allowed to be deducted in accordance with the tax laws and the exemptions and discounts included in the tax laws. Losses can be carried forward for a maximum of 5 years, to be deducted from the taxable profits that will arise in future years, However, the losses incurred cannot be deducted retrospectively from the profits of previous years.

The 7061 numbered law on the Amendment of Some Tax Laws was entered into force by being published in the Official Gazette dated 5 December 2017 and numbered 30261. With the 89th article of this Law, amendments are made in the 5th article titled "Exceptions" of the Corporate Tax Law. The first paragraph of the article; With paragraph (a), the 75% exemption applied to the earnings arising from the sale of real estates which were stated in the assets of the institutions for two full years has been reduced to 50%. This amendment was entered into force on 5 December 2017.

31 March 31 December
Current income tax liabilities 2025 2024
Current income tax expense 748,155,245 751,840,494
Less: prepaid taxes (91,186,220) (193,675,453)
Current income tax liability / (asset) 656,969,025 558,165,041

Income tax expense for the periods ended 31 March 2025 and 31 December 2024 comprised of the following items:

1 January - 1 January -
31 March 2025 31 March 2024
Current income tax expense (154,789,190) (4,988,969)
Deferred tax income / (expense) 18,230,119 187,156,853
Total tax income / (expense) (136,559,071) 182,167,884

Deferred Tax

The Group recognizes deferred tax assets and liabilities for temporary timing differences arising from the differences between the tax base legal financial statements and the financial statements prepared in accordance with TAS. These differences are generally due to the fact that some income and expense items are included in different periods in tax base financial statements and financial statements prepared in accordance with TAS, and these differences are stated below.

The tax rate used in the calculation of deferred tax assets and liabilities will be 25% for 2024, and 25% for 2025 taxation periods.

In Türkiye, the companies cannot declare a consolidated tax return, therefore subsidiaries that have deferred tax assets position were not netted off against subsidiaries that have deferred tax liabilities position and disclosed separately.

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 22 - INCOME TAXES (INCLUDING DEFERRED TAX ASSETS AND LIABILITIES) (Continued)

As of 31 March 2025, and 31 December 2024 the breakdown of the accumulated temporary differences related to the Group and the deferred tax assets and liabilities using the applicable tax rates are as follows:

Deferred tax asset /
Total temporary differences (liability)
31 March 31 December 31 March 31 December
2025 2024 2025 2024
Provisions for employee
termination benefits 388,658,949 383,892,983 80,581,061 95,973,247
Provisions for doubtful receivables 43,240,864 25,440,203 10,810,216 6,360,051
Provisions for lawsuits 4,186,342 3,974,602 1,046,586 993,651
Provision for unused vacations 73,412,061 76,570,317 18,353,015 19,142,580
Carry-forward tax losses (*) 276,933,590 623,955,508 49,848,046 112,311,992
Discount income from financing (196,310,040) (289,126,938) (49,077,511) (72,281,734)
Foundation and organization
expenses 927,144 1,020,440 231,786 255,110
Exchange rate difference activation 224,505,493 241,452,596 56,126,373 60,363,149
Net differences between the
carrying values and tax bases of
investment properties (2,641,050,164) (2,868,922,514) (660,262,541) (717,230,629)
Revaluation differences on
property, plant and equipment (4,606,579,831) (4,529,213,751) (901,947,343) (856,674,861)
Other (84,421,097) (421,991,135) (21,166,459) (105,497,784)
Deferred tax assets / (liabilities),
net (6,561,204,145) (6,729,144,137) (1,410,049,958) (1,450,334,340)

(*) As of 31 March 2025, based on the projections and future estimations, there is no previous year loss for which deferred tax is not recognized (31 December 2024: None).

The effects of the net presentation style of the Group's consolidated balance sheet were reflected on the group's consolidated balance sheet because they have clearly demonstrated the deferred tax assets and obligations in the financial statements of subsidiaries with separate taxpayers. The temporary differences in the table above and the deferred tax assets and obligations are prepared on the basis of gross values.

NOTE 23 - EARNING PER SHARE

1 January -
31 March 2025
1 January -
31 March 2024
Net gain for the year attributable to equity holders of the parent 112,076,281 519,237,693
Weighted average number of shares 662,000,000 662,000,000
Earning per share (TRY) 0,1693 0,7843

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 24 - BORROWINGS

31 March 31 December
Short term borrowings 2025 2024
Short term foreign currency loans 3,626,517,871 3,221,859,127
Short term local currency loans 659,897,964 1,011,214,902
Current portion of long-term financial liabilities 101,938,250 121,517,219
Short term lease labilities 115,863,039 89,011,695
4,504,217,124 4,443,602,942
31 March 31 December
Long term borrowings 2025 2024
Long term foreign currency loans 1,155,549,855 929,627,255
Long term lease labilities 118,238,526 176,271,854
1,273,788,381 1,105,899,109

As of 31 March 2025, and 31 December 2024 details of short and long-term bank loans are as follows:

31 March 2025
Original Currency Maturity (%) Original Amount TRY Equivalent
EUR April, 2025 – Jan, 2027 4,29 – 10.40 119,768,928 4,884,005,976
TRY April, 2025 – Sept, 2025 15,00 – 48,06 659,897,964 659,897,964
5,543,903,940
31 December 2024
Original Currency Maturity (%) Original Amount TRY Equivalent
USD Jan, 2025 4,90 - 6,00 359,204 13,973,166
EUR Jan, 2025 - Dec, 2026 4,29 - 11,00 105,204,055 4,259,030,434
TRY Jan, 2025 - Sept, 2025 26,93 - 57,72 1,011,214,902 1,011,214,902
5,284,218,502

Details of short and long-term lease liabilities are as follows:

31 March 2025
Original Currency Maturity (%) Original Amount TRY Equivalent
USD April, 2025 – Sept, 2025 5,25 1,615,875 61,024,504
EUR April, 2025 – Dec, 2027 11,96 – 14,04 2,141,921 87,180,254
TRY April, 2025 – Feb, 2028 16,83 – 49,00 85,896,807 85,896,807
234,101,565
31 December 2024
Original Currency Maturity (%) Original Amount TRY Equivalent
USD Jan, 2025 - Sept, 2025 5,25 1,934,894 75,268,082
EUR Jan, 2025 - Dec, 2027 11,96 - 14,04 2,319,054 93,934,998
TRY Jan, 2025 - Sept, 2028 16,83 - 49,00 96,080,470 96,080,470
265,283,550

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 25 - NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS

Currency Risk Management

The Group is exposed to currency risk on its operations that are denominated in other currencies.

The distribution of the Group's foreign currency denominated monetary and non-monetary assets and monetary and non-monetary liabilities as of the balance sheet date is as follows:

31 March 2025 TRY Equivalent USD EUR Other
1. Trade Receivables 935,954,455 23,922,061 799,065 -
2a. Monetary Financial Assets 574,673,921 8,539,652 4,710,571 123,871
2b. Non-monetary Financial Assets - - - -
3. Other 300,907,464 437,375 6,984,505 2,509
4. CURRENT ASSETS (1+2+3) 1,811,535,840 32,899,088 12,494,141 126,380
5. Trade Receivables - - - -
6a. Monetary Financial Assets 728,885 19,300 - -
6b. Non-monetary Financial Assets - - - -
7. Other - - - -
8. NON-CURRENT ASSETS (5+6+7) 728,885 19,300 - -
9. TOTAL ASSETS (4+8) 1,812,264,725 32,918,388 12,494,141 126,380
10. Trade Payables 3,881,289,135 17,008,909 79,260,894 120,129
11. Financial Liabilities 3,765,403,815 365,593 92,002,935 -
12a. Monetary Other Liabilities 52,008,513 1,192,987 168,568 -
12b. Non-Monetary Other Liabilities - - - -
13. CURRENT LIABILITIES (10+11+12) 7,698,701,463 18,567,489 171,432,397 120,129
14. Trade Payables - - - -
15. Financial Liabilities 1,266,806,919 1,250,282 29,907,913 -
16a. Monetary Other Liabilities 44,721,075 1,182,043 - -
16b. Non-Monetary Other Liabilities - - - -
17. NON-CURRENT LIABILITIES (14+15+16) 1,311,527,994 2,432,325 29,907,913 -
18. TOTAL LIABILITIES (13+17) 9,010,229,457 20,999,814 201,340,310 120,129
19 Off-balance Sheet Derivative Instruments
Net Asset/Liability Position (19a - 19b) - - - -
19a. Amount of active foreign derivative currency
off-balance sheet - - - -
19b. Amount of passive foreign derivative currency
off-balance sheet - - - -
20.Net Foreign Currency Assets/(Liabilities) (7,197,964,732) 11,918,574 (188,846,169) 6,251
Position (9-18+19)
21.Monetary Items Net Foreign Currency Assets
/ (Liabilities)(1+2a+3+5+6a-10-11-12a-14-15-16a)
22. Fair value of financial instruments used for - - - -
currency hedge
23. Hedged foreign currency assets - - - -
24. Export 658,707,255 14,202,188 3,038,572 2,298
24. Import (1,726,000,523) (1,392,497) (36,026,353) (111,543)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 25 - NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)

31 December 2024 TRY Equivalent USD EUR Other
1. Trade Receivables 945,021,873 23,974,908 339,235 7,164
2a. Monetary Financial Assets 621,651,904 8,610,877 6,955,897 124,149
2b. Non-monetary Financial Assets - - - -
3. Other 215,095,477 745,649 4,603,718 -
4. CURRENT ASSETS (1+2+3) 1,781,769,254 33,331,434 11,898,850 131,313
5. Trade Receivables - - - -
6a. Monetary Financial Assets 733,915 18,900 - -
6b. Non-monetary Financial Assets - - - -
7. Other - - - -
8. NON-CURRENT ASSETS (5+6+7) 733,915 18,900 - -
9. TOTAL ASSETS (4+8) 1,782,503,169 33,350,334 11,898,850 131,313
10. Trade Payables 3,235,046,021 6,964,477 73,213,457 82,402
11. Financial Liabilities 3,371,052,778 359,204 82,936,820 -
12a. Monetary Other Liabilities 110,608,041 1,312,292 1,474,408 -
12b. Non-Monetary Other Liabilities - - -
13. CURRENT LIABILITIES (10+11+12) 6,716,706,840 8,635,973 157,624,685 82,402
14. Trade Payables 4,875,913 125,344 - -
15. Financial Liabilities 1,071,153,901 1,934,894 24,586,289 -
16a. Monetary Other Liabilities 46,722,747 1,203,249 - -
16b. Non-Monetary Other Liabilities - - - -
17. NON-CURRENT LIABILITIES (14+15+16) 1,122,752,561 3,263,487 24,586,289 -
18. TOTAL LIABILITIES (13+17) 7,839,459,401 11,899,460 182,210,974 82,402
19 Off-balance Sheet Derivative Instruments
Net Asset/Liability Position (19a - 19b) - - - -
19a. Amount of active foreign derivative currency
off-balance sheet - - - -
19b. Amount of passive foreign derivative currency
off-balance sheet - - - -
20. Net Foreign Currency Assets/(Liabilities) (6,056,956,232) 21,450,874 (170,312,124) 48,911
Position (9-18+19)
21. Monetary Items Net Foreign Currency
Assets / (Liabilities)(1+2a+3+5+6a-10-11-12a-14-
15-16a) (6,056,956,232) 21,450,874 (170,312,124) (48,911)
22. Fair value of financial instruments used for
currency hedge
23. Hedged foreign currency assets - - - -
24. Export 3,181,731,588 67,920,118 9,193,268 12,510
24. Import (5,644,073,468) (14,673,379) (120,164,923) (281,032)

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 25 - NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)

Sensitivity Analysis to Currency Risk

The Group is mainly exposed to foreign currency risks in USD and EUR. The following table shows the Group's sensitivity to a 10% increase and decrease in USD and EUR, 10% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates. The sensitivity analysis only includes outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 10% change in foreign currency rates. This analysis comprises the borrowings used for foreign operations within the Group outside the functional currency. A positive number indicates an increase in profit / loss and other equity.

Profit/Loss
Appreciation foreign Depreciation foreign
31 March 2025 currency currency
In case of USD increases in 10% against TRY
1- USD net asset/liability 44,868,201 (44,868,201)
2- USD hedged portion (-) - -
3- Net effect of USD (1 +2) 44,868,201 (44,868,201)
In case of EUR increases in 10% against TRY
4- EUR net asset/liability (770,117,626) 770,117,626
5- EUR hedged portion (-) - -
6- Net effect of EUR (4+5) (770,117,626) 770,117,626
In case of other currencies increases in 10% against TRY
7- EUR net asset/liability 5,452,952 (5,452,952)
8- EUR hedged portion (-) - -
9- Net effect of other currencies (4+5) 5,452,952 (5,452,952)
TOTAL (3+6+9) (719,796,473) 719,796,473
Profit/Loss
Appreciation foreign Depreciation foreign
31 December 2024 currency currency
In case of USD increases in 10% against TRY
1- USD net asset/liability 75,603,765 (75,603,765)
2- USD hedged portion (-) - -
3- Net effect of USD (1 +2) 75,603,765 (75,603,765)
In case of EUR increases in 10% against TRY
4- EUR net asset/liability (626,868,262) 626,868,262
5- EUR hedged portion (-) - -
6- Net effect of EUR (4+5) (626,868,262) 626,868,262
In case of other currencies increases in 10% against TRY
7- EUR net asset/liability (54,431,127) 54,431,127
8- EUR hedged portion (-) - -
9- Net effect of other currencies (4+5) (54,431,127) 54,431,127
TOTAL (3+6+9) (605,695,624) 605,695,624

KEREVİTAŞ GIDA SANAYİ VE TİCARET A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2025 (Amounts expressed in the purchasing power of the Turkish Lira ("TRY") as of 31 March 2025, unless otherwise indicated.)

NOTE 25 - NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)

Interest Rate Risk Management

The Group's borrowings with fixed and variable interest rates exposes the Group to interest rate risk,

The interest rate profile of the Group's interest-bearing financial instruments are as follows:

31 March 31 December
Interest Position 2025 2024
Fixed interest rate instruments
Borrowings 5,778,005,505 5,549,502,051
Cash and cash equivalents (term deposits) 1,900,931,745 2,031,760,090
Trade receivables 4,000,250,358 3,899,010,458
Trade payables 5,791,912,350 5,514,561,231
Other payables 516,796,870 560,051,915
Variable interest rate instruments
Other receivables 6,583,962,129 6,933,970,967
Other payables 768,658,489 1,645,161,403

NOTE 26 - CASH AND CASH EQUIVALENTS

31 March 31 December
2025 2024
Cash at banks 2,100,089,496 2,209,708,389
- Demand deposits 199,157,751 177,948,299
- Time deposits (*) 1,900,931,745 2,031,760,090
Credit card receivables 19,810,042 111,509,674
2,119,899,538 2,321,218,063

(*) The maturity of the balances constituting the relevant amount is between April 2-4, 2025, and the interest rate for Turkish Lira-based time deposits is 38,00% - 45,00%, for Euro-based time deposits it is 0,75% and for US Dollar-based time deposits it is 1,85%. (December 31, 2024: The interest rate for TRY-based time deposits is 48,92%, and for EUR-based time deposits it is 1,25%)

NOTE 27 - SUBSEQUENT EVENTS

None.

……………………………………………………

Talk to a Data Expert

Have a question? We'll get back to you promptly.